Site Search

1. 131.
   AMP/assets/AMPComments_CY2019CLFS_PreliminaryDeterminations_FINAL.pdf?pass=75

   To assist CMS in finalizing the CY2019 determination, we provide a more detailed rationale for 1 https://www.law.cornell.edu/cfr/text/42/414.508 5 ... to code 81408 (Tier 2 MolPath, level 9) x 50%, which was supported by three members of the Panel and ... support for its crosswalk recommendation of 81408 X 50%. 81X81 codes for the full sequence analysis of BRCA1

   https://www.amp.org/AMP/assets/AMPComments_CY2019CLFS_PreliminaryDeterminations_...
2. 132.
   AMP/assets/File/advocacy/AMP_Comments_CMS-2018-0166_March_1_2019.pdf?pass=11

   AMP writes to you in support of the one-time adjustment, i.e., 20% increase, to both the certificate fees used to cover the general costs of administering ... part of this effort, AMP supports expanding the use of proficiency testing and 1 https://www.amp.org/advocacy/advocacy-resources/laboratory-developed-testing-procedures-ldps/ASSOCIATION FOR MOLECULAR

   https://www.amp.org/AMP/assets/File/advocacy/AMP_Comments_CMS-2018-0166_March_1_...
3. 133.
   AMP/assets/File/education/case-studies/0319_34-35_AMPcase_reprint-LR.pdf?pass=100

   In an attempt to increase screening rates, a broad coalition of more than 900 organizations developed the “80% by 2018” screening campaign. Despite these efforts, CRC screening rates remain ... cancer statistics review (CSR) 1975– 2014. National Cancer Institute. SEER website. https://seer.cancer.gov/csr/1975_2014. Updated April 2, 2018. 7.

   https://www.amp.org/AMP/assets/File/education/case-studies/0319_34-35_AMPcase_re...
4. 134.
   AMPlificiations July 2014

   To date 26% of requests have resulted in changes in the final LCD. Based on the positive impact of the comments ... Clinic,” will be presented by Birgit Funke on July 23 at 1:00pm (ET). Registration is free and online at: https://www2.gotomeeting.com/register/432160738. For a list of other upcoming webinars, visit: www.amp.org/Webinars/future_webinars.cfm

   https://www.amp.org/AMP/assets/File/newsletter/July2014.pdf?pass=37
5. 135.
   In-system clinical laboratories kept our hospitals open and solvent during COVID...

   benefit to our healthcare system (https://journals.sagepub.com/doi/10.1177/23742895211010253 ). First, COVID-19 testing provided an important revenue stream at ... 19 results permitted our institutions to resume routine care, and in fact allowed us to perform 89% of the surgeries projected for fiscal year 2020. This would have been impossible with a referral test

   https://www.amp.org/about/newsroom/amp-blog-content/in-system-clinical-laborator...
6. 136.
   AMP/assets/File/clinical-practice/CAP-IASLC-AMP_Lung_Molec_Testing_FAQ_APPROVED_20...

   in as little as 5% of viable cells. There is currently insufficient evidence to support a recommendation for or against routine testing for ALK mutational status ... International Association for the Study of Lung Cancer, and the Association for Molecular Pathology [published online January 22, 2018]. J Mol Diagn. https://doi.org/10.1016/j.jmoldx.2017.11.004

   https://www.amp.org/AMP/assets/File/clinical-practice/CAP-IASLC-AMP_Lung_Molec_T...
7. 137.
   AMP/assets/File/annualreports/AMPAnnualReport2015.pdf?pass=40

   Doctoral Scientists 5% Trainees Technologists Others Interested in Advancing ... Academic Medical Centers AMP members work in: 19% 8% 4% 10%14% 38% Public Policy 2015 was a busy year for ... Practices Practice Guidelines And Much More 10% 3% 39% 13% Trainees Technologists Others Interested in Advancing AMP ... at the AMP 2015 Annual Meeting. 35% Doctoral Scientists

   https://www.amp.org/AMP/assets/File/annualreports/AMPAnnualReport2015.pdf?pass=4...
8. 138.
   Microsoft PowerPoint - MPN

   Scale (% IS), used for monitoring ... gene testing for PV (95%), ET (50-70%), and PMF (30-50%) Exon 12 mutations (~5% of PV) Therapy: JAK2 inhibitors ... erythrocytosis High VAF (>75%) is associated with disease progression ... and S505N/A in ET (5%) and PMF (5-10%) p.W515K/L and S505N/A ... predominantly exon 17 Diagnosis: CNL (100%), other myeloid neoplasms Therapy: p.T618I

   https://www.amp.org/AMP/assets/File/education/MIMP/MPN.pdf?pass=88
9. 139.
   AMP/assets/File/education/case-studies/1116-AMPCaseReport-LR.pdf?pass=7

   CGAT results w/cnLOH of 11p in 30% of cells; no copy number ... hematopoiesis; minimal morphologic dysplasia ( 10% in all lineages), 4.5% CD34+ blasts by IHC 46 ... CD34+ myeloid blasts at 15.7% of the white cells, consistent ... neoplasm Hypercellular marrow with 19.4% blasts; marked megakaryocytic hypoplasia, with ... cnLOH of 11p in 20% of cells; no CNAs; PCR

   https://www.amp.org/AMP/assets/File/education/case-studies/1116-AMPCaseReport-LR...
10. 140.
    AMP/assets/2024_YIA_Abstracts.pdf?pass=78

    RPP30 was detected in ≥95% and HBB in ≥90% of samples from each condition. There ... identified in 9 azole-resistant isolates (12%), whereas HAPE p.P88L was identified in 1 azole-resistant isolate (1.3%). HMG2 p.I235S was identified in 20% (15/75) of azole-resistant isolates, but ... in 14 of the 60 specimens (23.33% positivity). Of the 14 positives, 13 were

    https://www.amp.org/AMP/assets/2024_YIA_Abstracts.pdf?pass=78